AIM AIM ImmunoTech Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.)

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☒

Check the appropriate box:

AIM IMMUNOTECH INC.

(Name of Registrant as Specified in Its Charter)

TED D. KELLNER

TODD DEUTSCH

ROBERT L. CHIOINI

PAUL W. SWEENEY

(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

PRELIMINARY COPY SUBJECT TO COMPLETION DATED OCTOBER 18, 2024

TED D. KELLNER

TODD DEUTSCH

ROBERT L. CHIOINI

PAUL W. SWEENEY

[●], 2024

Dear AIM Stockholders:

We are furnishing this Proxy Statement to holders of the common stock, par value $0.001 per share (the “Common Stock”), of AIM ImmunoTech Inc., a Delaware corporation (“AIM” or the “Company”), in connection with our solicitation of proxies for use at the 2024 Annual Meeting of Stockholders of the Company scheduled to be held at [●] Eastern Time, in virtual format, via live webcast, on [●], 2024, and at any adjournments, postponements or continuations thereof (the “Annual Meeting”).

This solicitation is being conducted by Ted D. Kellner, the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the “Kellner Group,” “we” or “us” and, as nominees, the “Kellner Group Nominees”). As of the date hereof, Mr. Kellner is the beneficial owner of 1,493,000 shares of Common Stock (1,000 of which shares he is the record owner of), Mr. Deutsch is the beneficial owner of 1,716,100 shares of Common Stock and Mr. Sweeney is the beneficial owner of 2,000 shares of Common Stock. Together, the beneficial ownership of the Kellner Group is 3,211,100 shares of Common Stock, or approximately [●]% of the [●] shares outstanding as of [●], 2024, the record date the Company has established for the Annual Meeting (the “Record Date”).

For the reasons set forth in the attached Proxy Statement, we believe significant changes to the composition of the Board of Directors of the Company (the “Board”) are necessary to ensure that the Company is overseen in a manner consistent with its stockholders’ best interests. Under the incumbent Board, AIM has experienced what we consider to be massive declines in its stock price (over 99% since 2016 when Mr. Equels, Dr. Mitchell and Mr. Appelrouth took control of the Board), irresponsible financial management and investor relations, inadequate clinical and commercial progress and significant net losses under the watch of the incumbent Board. Despite this, the incumbent Board has engaged in what we consider to be extremely wasteful entrenchment efforts and avoided any independent oversight or effective corporate governance while alienating stockholders and potential new investors. We believe AIM will only have a chance to be successful when it has a new Board that can serve as a respected steward of investor capital and earn the trust of existing and potential stockholders. We believe the past actions of the incumbent Board, highlighted by the ruling of the Delaware Supreme Court that the amended bylaws adopted by Mr. Equels, Dr. Mitchell and Mr. Appelrouth in 2023 were the “product of an improper motive and purpose, which constitutes a breach of the duty of loyalty,” are disqualifying in this respect.

Mr. Kellner is an accomplished executive and investor, successfully founding and, until his retirement, operating an asset management firm that currently has approximately $16.0 billion of assets under advisement. Mr. Deutsch has significant experience in financial markets and analysis from his decades’ long career in trading and investment, and currently serves on the board of directors and compensation committee of a publicly traded financial holding company. Mr. Chioini has an extensive life science background and, as founder and a chief executive officer of a publicly traded pharmaceutical drug and medical device company for over 20 years, has experience in operations, finance, successful clinical drug development, licensing, commercial sales, strategic planning, regulatory matters and public company governance. Mr. Sweeney has significant investment and management experience, and currently serves as a principal of a private equity firm he co-founded. We believe the Kellner Group Nominees would collectively bring a wealth of business, financial, clinical trial, life science and governance experience and much needed credibility to the Board.

The Company’s current Board is composed of four directors, each with terms expiring at the Annual Meeting. Through the attached Proxy Statement and enclosed GOLD proxy card, we are soliciting proxies to

elect each of the Kellner Group Nominees at the upcoming Annual Meeting. We ask that you cast your votes only FOR each of Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney on the GOLD proxy card – and disregard the WHITE proxy card provided by AIM.

Under rules adopted by the Securities and Exchange Commission (the “SEC” or the “Commission”), the enclosed GOLD proxy card also includes the names of incumbent directors nominated by the Company (the “Incumbent Nominees”). We ask that you only cast your votes FOR each of Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney. Stockholders should refer to the Company’s proxy statement, which is available, free of charge, at sec.gov, for the names, backgrounds, qualifications and other information concerning the Incumbent Nominees. There is no assurance that any of the Incumbent Nominees will serve as directors if all or some of our nominees are elected.

We urge you to carefully consider the information contained in the attached Proxy Statement and then support our efforts by signing, dating, and returning the enclosed GOLD proxy card today.

If you have already voted for the Incumbent Nominees, we urge you to change your vote by signing, dating, and returning a later dated GOLD proxy or by voting electronically for the Kellner Group Nominees at the Annual Meeting.

If you have any questions or require any assistance with your vote, please contact Okapi Partners, which is assisting us, at its address and toll-free number listed below.

If you have any questions, require assistance in voting your GOLD proxy card, or need additional copies of our proxy materials, please contact Okapi Partners at the phone numbers or email address listed below.

Okapi Partners LLC

1212 Avenue of the Americas, 17th Floor,

New York, New York 10036

Stockholders may call toll-free: (844) 343-2621

Banks and brokers call: (212) 297-0720

Email: info@okapipartners.com

PRELIMINARY COPY SUBJECT TO COMPLETION DATED OCTOBER 18, 2024

2024 ANNUAL MEETING OF STOCKHOLDERS

OF

AIM IMMUNOTECH INC.

PROXY STATEMENT

OF

TED D. KELLNER

TODD DEUTSCH

ROBERT L. CHIOINI

PAUL W. SWEENEY

PLEASE SIGN, DATE AND MAIL THE ENCLOSED GOLD PROXY CARD TODAY

We are furnishing this Proxy Statement to holders of the common stock, par value $0.001 per share (the “Common Stock”), of AIM ImmunoTech Inc., a Delaware corporation (“AIM” or the “Company”), in connection with our solicitation of proxies for use at the 2024 Annual Meeting of Stockholders of the Company scheduled to be held at [●], Eastern Time, in a virtual format, via live webcast, on [●], 2024, and at any adjournments, postponements or continuations thereof (the “Annual Meeting”).

This solicitation is being conducted by Ted D. Kellner, the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the “Kellner Group,” “we” or “us” and, as nominees, the “Kellner Group Nominees”). As of the date hereof, Mr. Kellner is the beneficial owner of 1,493,000 shares of Common Stock (1,000 of which shares he is the record owner of), Mr. Deutsch is the beneficial owner of 1,716,100 shares of Common Stock and Mr. Sweeney is the beneficial owner of 2,000 shares of Common Stock. Together, the beneficial ownership of the Kellner Group is 3,211,100 shares of Common Stock, or approximately [●]% of the [●] shares outstanding as of [●], 2024, the record date the Company has established for the Annual Meeting (the “Record Date”).

Mr. Kellner has nominated himself and the other Kellner Group Nominees to the Company’s Board of Directors (the “Board”) because he believes that significant change to the composition of the Board is needed to ensure that the interests of the stockholders are appropriately represented in the boardroom. The Kellner Group Nominees have strong, relevant backgrounds and are committed to fully unlocking and maximizing stockholder value. We are seeking your support at the Annual Meeting for the following purposes:

This Proxy Statement and the enclosed GOLD proxy card are first being furnished to stockholders on or about [●], 2024.

According to the Company’s proxy statement, only stockholders of record at the close of business on the Record Date are entitled to notice of and to vote at the Annual Meeting. You are entitled to attend the Annual

1

Meeting only if you were a stockholder as of the close of business on the Record Date or if you hold a valid proxy for the Annual Meeting. According to the Company’s proxy statement, you will be able to attend the Annual Meeting in a virtual format. You will not be able to attend the Annual Meeting in person. To participate, vote or submit questions during the Annual Meeting via a live webcast, you must pre-register at [●] by [●], Eastern Time on [●], 2024. Upon completing registration, participants will receive further instructions via email, including unique links that will allow them to access the meeting. Stockholders may log into the meeting platform beginning at [●], Eastern Time, on [●], 2024. Please see the “Virtual Meeting” section of this Proxy Statement for additional information.

The Company’s current Board is composed of four directors, each with terms expiring at the Annual Meeting. Through this Proxy Statement and enclosed GOLD proxy card, we are soliciting proxies to elect each of the Kellner Group Nominees. We ask that you cast your votes only FOR Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney on the GOLD proxy card and disregard the WHITE proxy card provided by AIM.

Under rules adopted by the Securities and Exchange Commission, the enclosed GOLD proxy card also includes the names of incumbent directors nominated by the Company (the “Incumbent Nominees”). We ask that you only cast your votes FOR Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney. See the “Voting and Proxy Procedures” section of this Proxy Statement for additional information. Stockholders should refer to the Company’s proxy statement, which is available, free of charge, at sec.gov, for the names, backgrounds, qualifications, and other information concerning the Company’s nominees. If elected, the Kellner Group Nominees will constitute the full Board and will be able to implement any actions that they may believe are necessary to unlock stockholder value.

Mr. Kellner, Mr. Deutsch and Mr. Sweeney intend to vote all of the shares of Common Stock they own “FOR” the Kellner Group Nominees only, “FOR” the ratification of the independent registered public accounting firm for the 2024 fiscal year, and “AGAINST” the advisory vote approving executive compensation as described herein. Stockholders should understand, however, that all shares of Common Stock represented by the enclosed GOLD proxy card will be voted at the Annual Meeting as marked.

According to the Company’s proxy statement, on the Record Date, there were [●] shares of Common Stock outstanding. Each stockholder is entitled to one vote for each share of Common Stock held by such stockholder on the Record Date. The mailing address of the principal executive offices of the Company is 2117 SW Highway 484, Ocala, Florida 34473.

THIS SOLICITATION IS BEING MADE BY THE KELLNER GROUP AND NOT ON BEHALF OF THE BOARD OF DIRECTORS OR MANAGEMENT OF THE COMPANY. WE ARE NOT AWARE OF ANY OTHER MATTERS TO BE BROUGHT BEFORE THE ANNUAL MEETING OTHER THAN AS SET FORTH IN THIS PROXY STATEMENT. SHOULD OTHER MATTERS, WHICH WE ARE NOT AWARE OF A REASONABLE TIME BEFORE THIS SOLICITATION, BE BROUGHT BEFORE THE ANNUAL MEETING, THE PERSONS NAMED AS PROXIES IN THE ENCLOSED GOLD PROXY CARD WILL VOTE ON SUCH MATTERS IN OUR DISCRETION.

WE URGE YOU TO SIGN, DATE AND RETURN THE GOLD PROXY CARD IN FAVOR OF THE ELECTION OF EACH OF THE KELLNER GROUP NOMINEES.

IF YOU HAVE ALREADY SENT A PROXY CARD FURNISHED BY COMPANY MANAGEMENT OR THE BOARD, YOU MAY REVOKE THAT PROXY AND VOTE ON EACH OF THE PROPOSALS DESCRIBED IN THIS PROXY STATEMENT BY SIGNING, DATING, AND RETURNING THE ENCLOSED GOLD PROXY CARD. THE LATEST DATED PROXY IS THE ONLY ONE THAT COUNTS. ANY PROXY MAY BE REVOKED AT ANY TIME PRIOR TO THE ANNUAL MEETING BY DELIVERING A WRITTEN NOTICE OF REVOCATION OR A LATER DATED PROXY FOR THE ANNUAL MEETING OR BY VOTING AT THE ANNUAL MEETING.

2

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting – This Proxy Statement and our GOLD proxy card are available at:

[●]

3

IMPORTANT

Your vote is important, no matter how few shares of Common Stock you own. We urge you to sign, date, and return the enclosed GOLD proxy card today to vote FOR the election of the Kellner Group Nominees.

IMPORTANT: Only your latest dated proxy card will count, so we urge you to disregard and not return any WHITE proxy card you receive from the Company and return only the GOLD proxy card. NOTE: Even if you return the management WHITE proxy card marked “WITHHOLD” just as a protest against the Incumbent Nominees, it will revoke any GOLD proxy card you may have previously sent to us so we urge you to disregard and not to return any WHITE proxy card you receive from the Company.

If you have any questions, require assistance in voting your GOLD proxy card, or need additional copies of our proxy materials, please contact Okapi Partners at the phone numbers or email address listed below.

Okapi Partners LLC

1212 Avenue of the Americas, 17th Floor,

New York, New York 10036

Stockholders may call toll-free: (844) 343-2621

Banks and brokers call: (212) 297-0720

Email: info@okapipartners.com

4

BACKGROUND TO THE SOLICITATION

The following explains the background of material events leading up to this proxy solicitation.

Mr. Kellner and Mr. Deutsch’s Involvement with AIM Prior to Meeting Mr. Chioini:

5

Mr. Chioini’s Prior Involvement with Nomination Efforts:

6

7

Background of Kellner Group’s Nominations:

8

9

10

11

REASONS FOR THE SOLICITATION

AIM is an immuno-pharma company that focuses primarily on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune disorders. The Company’s lead product is an investigational drug called Ampligen (rintatolimod). AIM has been focused on preclinical and clinical activities with respect to Ampligen since 1987. To date, Ampligen has not been approved for sale in the United States nor generated any meaningful revenues.

The Company is publicly traded on the NYSE American under the stock symbol “AIM.” Since Mr. Equels became AIM’s CEO on February 25, 2016, and since current Board members Mr. Equels, Dr. Mitchell and Mr. Appelrouth assumed control of the Board later that year, AIM has experienced massive declines in its stock price and significant net losses, based on what we believe to be irresponsible financial management and investor relations and inadequate clinical and commercial progress. Despite this, incumbent Board members have engaged in what we consider to be extraordinary efforts to avoid accountability to stockholders, wasting significant corporate resources in their entrenchment efforts.

We believe AIM will only have a chance to be successful when it has a Board with the discipline and expertise necessary to oversee a focused long-term clinical and commercialization program and that can serve as a respected steward of investor capital and earn the confidence of stockholders and potential new investors. Collectively, we believe the Kellner Group Nominees would bring a wealth of business, financial, clinical trial, life science and corporate governance experience and much needed credibility to the Board.

We intend to enhance the value of AIM by:

The case for a significant change in the Board is simple. We believe the incumbent Board’s failures are numerous, including a massive decline in stockholder value on its watch, engaging in wasteful conduct to avoid accountability to stockholders and breaching its fiduciary duty of loyalty in the process, irresponsible financial

12

management and investor relations, inadequate clinical and commercial progress, excessive compensation and a lack of effective corporate governance. We believe the incumbent Board, rather than focusing on ways to improve performance and generate value for stockholders, is determined to continue to entrench itself and resist accountability to stockholders at all costs.

AIM’s Stock Price Has Suffered Massive Declines

On February 25, 2016, the day that Mr. Equels assumed the role of CEO, AIM’s stock closed at $87.15. On September 30, 2016, the day that the three incumbent directors – Mr. Equels, Dr. Mitchell and Mr. Appelrouth – assumed control of the Board, AIM’s stock closed at $55.44 per share.¹

In the ensuing years, the value of AIM’s stock has plummeted. On October 15, 2024, AIM’s stock closed at $0.26 per share. In other words, the value of AIM’s stock has declined by over 99% since Mr. Equels became CEO and Mr. Equels, Dr. Mitchell and Mr. Appelrouth assumed control of the Board. The stock price has continued to decrease and reach new lows, including another 40% decline thus far in 2024 alone (from a $0.44 closing price on December 29, 2023). In order to avoid getting delisted from the NYSE American, AIM has undertaken reverse stock splits cumulating to a ratio of 1-for-528 (a 1-for-12 reverse split in 2016 and a 1-for-44 reverse split in 2019).

By contrast, the Russell 2000 Index has increased by approximately 117% since Mr. Equels became CEO (from $1,031.58 on February 25, 2016 to $2,246.52 on October 15, 2024) and approximately 79% since the incumbent directors assumed control of the Board (from $1,251.65 on September 30, 2016). In addition, the Nasdaq Biotechnology Index increased by approximately 77% (from $2,712.13 to $4,802.18) and 59% (from $3,027.15 to $4,802.18), respectively.

This dramatic drop in stockholder value, while the broader small capitalization and biotechnology markets have appreciated, is depicted in the following chart:

Entrenchment Efforts and Lack of Accountability to Stockholders

Despite abysmal stock price performance under its watch, the incumbent Board has engaged in what we consider to be unconscionable efforts to avoid accountability to stockholders and entrench itself at all costs.

13

At the past two annual meetings of stockholders, we believe AIM’s stockholders have made their dissatisfaction with the incumbent Board abundantly clear. At the 2022 Annual Meeting, uncontested, Mr. Equels’ “for” votes represented only approximately 16% of shares eligible to vote, Dr. Mitchell’s and Mr. Appelrouth’s “for” votes each represented only approximately 9% of shares eligible to vote.² At the 2023 Annual Meeting, uncontested, Mr. Equels’ and Ms. Bryan’s “for” votes each represented only approximately 21% of shares eligible to vote, and Dr. Mitchell’s and Mr. Appelrouth’s “for” votes represented only approximately 13% and 14% of shares eligible to vote, respectively.³ Moreover, the last three say-on-pay results have failed with approval rates ranging from 16% to 37%.⁴ Although the proxies received by the ASFV Committee with respect to the 2022 Annual Meeting and by Mr. Kellner, Mr. Deutsch and Mr. Chioini with respect to the 2023 Annual Meeting were ultimately disregarded and not voted, together with the aforementioned publicly disclosed results, we believe they clearly demonstrate that stockholders demand change in the Board.

In the face of this overwhelming lack of support from stockholders, the incumbent Board has gone to great lengths to avoid accountability and entrench itself. After the 2022 Annual Meeting, despite a public pledge to add two independent directors and improve corporate governance, the incumbent Board ratcheted up its entrenchment effort by adopting the 2023 Amended Bylaws. The Delaware Supreme Court ruled that the incumbent Board’s motive in adopting the 2023 Amended Bylaws was not to counter the threat of an uninformed vote. Rather, the Board’s “primary purpose was to interfere with [Mr. Kellner’s] nomination notice, reject his nominees, and maintain control.” The Delaware Supreme Court ruled that the 2023 Amended Bylaws were the “product of an improper motive and purpose, which constitutes a breach of the duty of loyalty.”

The Florida federal court also sanctioned AIM and its counsel for certain actions taken in the Florida Section 13(d) Action after finding that AIM and its counsel committed sanctionable conduct by continuing to pursue arguments that were “factually and legally frivolous and advanced for an improper purpose” and that certain defendants in that action were entitled to fee reimbursement.

The amount that the incumbent Board has spent on this effort to continue to entrench itself and to thwart the will of its stockholders – in furtherance of its improper purpose and breach of duty of loyalty in our view – is shocking to us. From 2021 to 2023, general and administrative expenses increased from $8.6 to $21.1 million (almost twice 2023 research and development expenses of $10.9 million).⁵ Legal expenses increased by $4.5 million in 2022, and again by $6.5 million more in 2023.⁶ Based on the foregoing, we estimate that the Company has spent over $15.0 million in the past two years in this bad faith effort.⁷

It is worth emphasizing that the incumbent Board never made any attempt to avoid this wasteful spending. In fact, the incumbent Board initiated and perpetuated it. AIM sued Mr. Kellner and Mr. Deutsch, two of its largest stockholders, in the Florida Section 13(d) Action in 2022 without attempting to engage with them in a meaningful way and has continued to pursue this action despite multiple dismissals and sanctions against AIM and its counsel. Mr. Chioini’s efforts to engage with the incumbent Board after the 2022 Annual Meeting were ignored. The incumbent Board then rejected Mr. Kellner’s 2023 Notice without any attempt at engagement whatsoever with two of AIM’s largest stockholders, resulting in massive legal expenses.

14

We believe the amount of funds that the incumbent Board has been willing to waste without even making an attempt at dialogue in prior years is unconscionable and clearly indicative of the incumbent Board’s improper motives.

Irresponsible Financial Management and Investor Relations

The Board’s actions, which as noted above we believe were in furtherance of its breach of the fiduciary duty of loyalty, have worsened the Company’s already precarious financial condition. As of June 30, 2024, AIM had $10.1 million of cash, cash equivalents and marketable securities, but also $5.5 million of accounts payable (largely, we believe, due to unpaid legal expenses from the Kellner Delaware Action).⁸ This results in effective liquidity of less than $5.0 million, providing a very short runway considering that AIM utilized $7.8 million in cash from operations in the first six months of 2024.⁹ As noted above, we believe that the incumbent Board put the Company in this distressed financial position as a result of its entrenchment efforts.

As a result, the incumbent Board now pursues what we consider to be vanishing, highly dilutive and increasingly desperate financing alternatives to the detriment of stockholders. In just the last few months, such transactions have included:

15

We believe these financings, which do not include the dilutive stock issuances to Mr. Equels and Mr. Rodino described below, have done little to alleviate the Company’s financial distress, but are incredibly damaging to future prospects. In the short term, we believe the additional shares being sold into the market by the Company or short-term investors create downward pressure on the stock price, hampering the ability to raise additional funds at attractive prices. In the longer term, we believe the significant overhang caused by the 20.5 million shares underlying warrants will continue weigh down the stock price. In our view, this cycle can only be broken by earning the trust of the investment community and attracting long-term investment. We do not believe the incumbent Board is capable of doing this.

Inadequate Clinical and Commercial Progress

As noted above, AIM has been developing Ampligen since 1987. Across parts of five different decades of clinical development work with Ampligen, AIM has failed to generate meaningful regulatory approval or sales. While AIM has continued to tout all the different diseases Ampligen can treat, we believe the reality is that AIM remains a long way away from any realistic chance of meaningful regulatory approvals and commercialization due to a lack of focus, urgency and expertise in advancing clinical programs during the eight years that Mr. Equels, Dr. Mitchell and Mr. Appelrouth have controlled the Board (or during the 16 years that Mr. Equals and Dr. Mitchell have served on the Board together, or during the 26 years that Dr. Mitchell has served on the Board).

We believe that AIM’s key value driver is Ampligen, and its progress via clinical trial execution should be the number one strategic priority for AIM’s Board and management. Yet, in each of the last three fiscal years, AIM’s general and administrative spending has exceeded research and development spending.¹⁵ In 2023, general and administrative spending increased to $21.1 million, while research and development spending only increased to $11.0 million.¹⁶ This has continued into the first half of 2024, with general and administrative spending through June 30, 2024 of $6.4 million more than doubling research and development expenses of $3.1 million.¹⁷

We believe that the research and development spending that AIM has incurred is inadequate and not productive. Although we believe that one of Ampligen’s promising aspects is its potential to treat multiple types of diseases, it is our view that AIM’s approach of exploring numerous and varied potential indications through collaborations and third-party agreements and diverting focus and attention based on current events, rather than investing the necessary corporate resources and consistently committing to the most promising indications, has been ineffective.

This mismanagement and lack of progress has been overseen by the incumbent Board. Dr. Mitchell has served on the Board for 26 years since 1998 (and prior to that served on the Board as early as 1987). Mr. Equels has served on the Board for 16 years since 2008. Mr. Appelrouth has served on the Board for eight years since 2016, but consulted for the Board’s audit committee for five prior years going back to 2011.

Lack of Oversight and Effective Governance

For almost seven years, from 2016 to 2023, there were only three directors on the Board. Dr. Mitchell and Mr. Appelrouth, as the Company’s two non-executive directors, served as the sole members of the compensation committee, the audit committee and the corporate governance and nomination committee. Dr. Mitchell and Mr. Equels have served on the Board together for 16 years, and Mr. Appelrouth working with them for 13 of

16

those years (five years as a paid consultant and eight years as a director). Mr. Appelrouth also had a relationship with Mr. Equels prior to his appointment in 2016, having provided personal tax return services to Mr. Equels and his spouse and had also been retained by both Mr. Equels and his spouse to provide expert services in connection with their law practices. We do not believe this structure and composition provided any meaningful oversight of management and was disastrous for stockholders. In 2023, these three directors adopted the 2023 Amended Bylaws, which, as described above, the Delaware Supreme Court found served an improper motive and purpose and constituted a breach of the duty of loyalty.

AIM announced in November 2022, following the 2022 Annual Meeting, that it would seek to add two independent and qualified directors to the Board. However, this did not occur, and it demonstrates in our view that the incumbent Board is committed to continuing its past practices and even escalating its egregious entrenchment efforts and hostility to stockholders. AIM appointed just one new director – Ms. Bryan – in March 2023. Ms. Bryan was identified and recommended by Mr. Equels, had a pre-existing relationship with Mr. Equels and AIM through her role with BioFlorida, Inc. and no public company board experience.

We believe that the fact that the incumbent directors would not bring a true outside voice onto the Board, someone who did not have pre-existing relationship with Mr. Equels and the Company, is very telling and indicates that we should expect more of the same entrenchment and stockholder alienation from the Board. It is our view that the incumbent Board will resist independent oversight at all costs and is willing to burn through whatever funds are available in the corporate treasury to avoid accountability.

Excessive Compensation

Notwithstanding the massive stock price declines and what we consider inadequate clinical progress and financial mismanagement during their tenures, Mr. Equels, Dr. Mitchell and Mr. Appelrouth have cashed in handsomely at stockholders’ expense. Director and executive compensation from 2016 through 2023 has totaled approximately $21.5 million (based on amounts included in summary compensation tables for executives and director compensation tables for directors in SEC filings), compared to over $100 million in net loss during that time period.¹⁸

We believe the vast majority of AIM’s stockholders share our disgust with these compensation practices, as evidenced by the last three say-on-pay votes, with approval rates ranging from 16% to 37% of votes cast (including abstentions).¹⁹ Following deteriorating say-on-pay results at the 2020 annual meeting of stockholders, the Board responded by awarding Mr. Equels with a massive compensation increase, resulting in his reported 2020 compensation tripling to $2.7 million.²⁰ Following the 2021 annual meeting of stockholders and first failed say-on-pay vote, the Board did not communicate any remedial actions it would take in response. Instead, it awarded off-cycle option grants several months later in March 2022. Following the 2022 Annual Meeting and yet another overwhelming say-on-pay failure, AIM did announce that the compensation committee would engage a nationally recognized independent compensation consultant to review executive compensation and, if appropriate, consider adjustments. However, according to the AIM proxy statement for the 2023 Annual Meeting, rather than engaging a new compensation consultant, AIM requested that its previously engaged compensation consultant conduct a new assessment and did not disclose any changes to executive compensation as a result.

AIM reported lower executive compensation in 2023 as compared to 2022, but the difference appears to be primarily a result of 2023 bonus compensation being deferred to 2024.²¹ No transparency has been provided

17

about the timing or amount of such bonus. In addition, more recently, as it became clear that AIM would be facing another proxy contest, the incumbent Board in August and September 2024 issued Mr. Equels approximately 690,000 fully vested shares (more than 1% of outstanding shares) in August and September 2024 in lieu of $200,000 of annual base salary he would otherwise receive in the next year. An additional approximately 190,000 fully vested shares were issued to Mr. Rodino for similar purposes. While AIM certainly has a need to preserve cash, the timing of these issuances and the fact that they were made upfront – in advance of the salary that would be forgone in the next year (and thus in advance of the Record Date) – indicate to us that the incumbent Board is continuing its improper purpose and illegal entrenchment effort.

Mr. Equels’s significant compensation increase in 2020 was accompanied by a new employment agreement which also provides for what we see as outrageous severance benefits – salary and other benefits (including equity compensation) for the full five-year term in the event of a termination without cause (and a three-year extension of the term and accompanying severance benefits in the event of a termination without cause following a change of control). As a result, the potential severance payments to Mr. Equels in the event of a termination without cause (as disclosed in the Company’s annual executive compensation disclosure in its SEC reports) increased from $0.8 million, assuming a January 1, 2020 termination date (whether or not following a change of control), to $2.6 million (without a change of control) and $5.0 million (with a change of control), assuming a January 2, 2024 termination date. The foregoing is based on what was reported by AIM in the 2023 Annual Report. This does not even include the 3% of gross proceeds that Mr. Equels is entitled to for certain significant events and the sale of the Company or substantially all of its assets, which we view as highly atypical.

* *  *

For AIM to have any chance of success, we believe that significant change in the Board is urgently needed. We do not believe stockholders (and potential investors, importantly) have any faith in the incumbent Board’s abilities or motivations. This was evident in the voting results at the 2022 and 2023 Annual Meetings. We believe that the finding of the Delaware Supreme Court that Mr. Equels, Dr. Mitchell and Mr. Appelrouth breached their fiduciary duty of loyalty, and the extreme waste of corporate assets in the process and the resulting distressed financial condition of the Company, exacerbate these concerns.

We believe AIM will only have a chance to be successful when it has a Board with the discipline and expertise necessary to oversee a focused long-term clinical and commercialization program and that can serve as a respected steward of investor capital and earn the trust of existing and potential stockholders. Collectively, we believe the Kellner Group Nominees would bring a wealth of business, financial, clinical trial, life science and governance experience and much needed credibility to the Board.

18

PROPOSAL 1

ELECTION OF DIRECTORS

The Company’s current Board is composed of four directors, each with terms expiring at the Annual Meeting. The directors are each elected for a term of one year or until his or her successor is duly elected and qualified or his or her earlier death, resignation or removal. We are seeking your support at the Annual Meeting to elect Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney. You should refer to the Company’s proxy statement, which is available, free of charge, at sec.gov, for the names, background, qualifications and other information concerning the Incumbent Nominees.

With respect to the election of directors, the 2024 Amended Bylaws provide that a plurality of the votes cast by the stockholders present or represented by proxy at the meeting and entitled to vote is required to elect a director. Therefore, the four director nominees that receive the highest number of affirmative “FOR” votes will be elected as directors.

The Kellner Group Nominees

The following information sets forth the name, age, business address, present principal occupation, and employment and material occupations, positions, offices, or employments for the past five years of each of the Kellner Group Nominees. Each of the Kellner Group Nominees is a citizen of the United States.

Ted D. Kellner, age 78, currently manages his personal and family investments after retiring in 2017 from his career as a portfolio manager at Fiduciary Management, Inc., an investment management firm that he founded in 1980. Fiduciary Management, Inc. currently manages approximately $16 billion in assets, pension and profit-sharing trusts, Taft-Hartley and public funds, endowments and personal trusts throughout the United States. He is also the Chairman of Fiduciary Real Estate Development Inc., a business founded by Mr. Kellner in 1984 that owns and manages over $1.8 billion in multi-family residential units. Mr. Kellner previously served as a director of Metavante Technologies, Inc., a then publicly-traded company that provided banking and payments technologies to financial services firms, from 2007 to 2009, and Marshall & Ilsley Corporation, a then publicly-traded bank and financial holding company, from 2000 to 2011. He also served as a director of each of the American Family Mutual Insurance Company from 2001 to 2018, and currently serves on the board of the Kelben Foundation, a family foundation focused on education and health programs. In addition, Mr. Kellner has received the Chartered Financial Analyst designation from the CFA Institute. Mr. Kellner is qualified to serve as a director due to his over 50 years of investment and financial experience, and substantial senior management experience.

Todd Deutsch, age 52, is a private investor and entrepreneur. Since 2012, Mr. Deutsch has managed his family office. Beginning in 2024, Mr. Deutsch has also been a trader with Aramas Capital on a contract basis. From 2009 to 2012, Mr. Deutsch was the Portfolio Manager/Principal at Bascom Hill Partners, a wealth management services company. Prior to running his family office and Bascom Hill Partners, Mr. Deutsch spent 20 years as a trader with Goldman Sachs and various hedge funds. Mr. Deutsch has been a member of the board of directors of Esquire Financial Holdings, Inc., a publicly-traded financial holding company, since 2015 and serves on its Compensation Committee. Mr. Deutsch is qualified to serve as a director due to his extensive financial and business experience as well as valuable insight into managing and overseeing a business.

Robert L. Chioini, age 60, is the Managing Member of Bright Rock Holdings, LLC, a consultancy business founded by Mr. Chioini in 2019 that helps pharmaceutical drug and medical device companies successfully grow their businesses by providing financing, public listing, management, operations, licensing, clinical drug development, medical device development and corporate governance assistance, among other things. Mr. Chioini served as the Chief Executive Officer and a director of SQI Diagnostics, Inc. (OTCQX-US: SQIDF/TSX-V: SQD) from 2020 to 2021, a publicly-traded, vertically integrated diagnostic medical device company

19

servicing the U.S. and Canadian diagnostic healthcare markets, where he provided executive leadership and revamped the business leading to a 200% increase in company valuation to a $155 million market capitalization. Mr. Chioini served as Chairman of the Board and Chief Executive Officer of Rockwell Medical, Inc. (NASDAQ: RMTI) (“Rockwell”), a publicly-traded pharmaceutical drug and medical device company that Mr. Chioini founded, from 1995 to 2018, where he provided executive leadership and built the business into a successful, publicly-traded, vertically integrated company with four manufacturing plants, five distribution facilities and 330 employees servicing the U.S. and global dialysis healthcare markets becoming the 2^nd largest dialysate supplier in U.S. that reached $980 million in valuation in 2015. At Rockwell, Mr. Chioini obtained 14 new U.S. FDA medical device approvals, assembled top-level clinical talent and successfully raised over $150 million to fund and execute successful human clinical studies for drug development and obtained four new U.S. FDA drug approvals (3-NDA, 1-ANDA). In addition, he managed global business development for Rockwell and secured multiple exclusive license agreements to commercialize products internationally that realized in aggregate approximately $100 million in upfront cash payments and milestone payments, plus ongoing sales royalties, drug purchases, profit split and equity purchase, with companies like Baxter International, Inc. and Wanbang Biopharmaceutical (a subsidiary of Shanghai Fosun Pharmaceutical Group Co., Ltd.). Mr. Chioini was responsible for leading all operations and strategic direction for Rockwell with full accountability for bottom-line factors. Mr. Chioini is qualified to serve as a director due to his experience spanning all phases of starting and building a business, from inception into a successful, vertically integrated, publicly-traded pharmaceutical drug and medical device company, which included leading successful clinical development programs that resulted in four FDA approved drugs and multiple license partner agreements.

Paul Sweeney, age 59, is the co-founder and has served as a principal of PS Capital Partners, a private equity firm with a focus in manufacturing and process-oriented industries, since 2001. Prior to this, Mr. Sweeney was a founding partner at Horizon Partners, Ltd., a middle market buyout firm, from 1988 to 2001. Previously, Mr. Sweeney served in the corporate development group of Arthur Young & Co., an accountancy firm that later merged with Ernst & Young Global Limited, from 1987 to 1988. Mr. Sweeney currently serves as a director of numerous portfolio companies of PS Capital Partners, including Milwaukee Composites, Inc., a manufacturer of composite products for mass transit vehicles, since 2004; Waukesha Metal Products, a metal stamping and fabrication company, since 2005; PAX Holdings, a packaging manufacturer, since 2007; International Thermal Systems, an industrial oven manufacturer, since 2010; JTS Direct LLC, an advertising print company, since 2011; CM Global, a promotional products supplier, since 2012; Sussek Machine Company, a machining and assembly company, since 2012; Engineered Custom Coatings, LLC, a liquid coatings manufacturer, since 2017; Pack Logix, a contract manufacturing and packaging company, since 2018; Quick & Pure Ice Systems, an ice production company, since 2021; Soaris, a powersport engine and vehicle solutions manufacturer, since 2022; Maynard Steel Casting Co., a castings manufacturer, since 2022; and Forward Health, a Wisconsin Department of Health Services health care and nutritional assistance benefit program, since 2023. In addition, Mr. Sweeney serves on or has served on the board of directors of various other organizations, including Milwaukee World Festival, Inc., a festival and event management company; Wisconsin Bank & Trust, a wholly owned subsidiary of Heartland Financial USA, Inc., a publicly traded bank holding company with $20 billion in assets; Metropolitan Milwaukee Association of Commerce, a non-profit business organization; Milwaukee Scholars Charter School, a public charter school; and is a member of the Greater Milwaukee Committee, a non-profit civic organization. Mr. Sweeney received a bachelor’s of science degree in finance from Georgetown University’s School of Business Administration in 1987. In addition, Mr. Sweeney completed the 16th Annual Venture Capital Institute Seminar in 1990. Mr. Sweeney is qualified to serve as a director due to his extensive investment and management experience.

The principal business address of Mr. Kellner is 790 North Water Street, Suite 2175, Milwaukee, WI 53202. The principal business address of Mr. Deutsch is 7 Old Wagon Lane, Old Westbury NY 11568. The principal business address of Mr. Chioini is 1530 Forest Bay Ct., Wixom, MI 48393. The principal business address of Mr. Sweeney is 758 North Broadway, Suite 241, Milwaukee, WI 53202.

20

The Kellner Group believes that each of its nominees presently is, and if elected as a director of the Company, would qualify as, an “independent director” within the meaning of (i) applicable NYSE American listing standards applicable to board composition (and applicable committees thereof) and (ii) Section 301 of the Sarbanes-Oxley Act of 2002. Notwithstanding the foregoing, the Kellner Group acknowledges that no director of an NYSE American listed company qualifies as “independent” unless the Board affirmatively determines that such director is independent under such standards. Accordingly, the Kellner Group acknowledges that if any of its nominees is elected, the determination of the nominee’s independence ultimately rests with the judgment and discretion of the Board.

Other than as stated in this Proxy Statement, there are no arrangements or understandings between members of the Kellner Group and any other person or persons pursuant to which the nomination of the Kellner Group Nominees described herein is to be made. The Kellner Group Nominees have consented to be named in this Proxy Statement and agreed to serve as directors if elected. Except as set forth in this Proxy Statement (including with respect to the Jorgl Delaware Action and the Florida Section 13(d) Action), none of the Kellner Group Nominees is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries in any material pending legal proceedings. See “Background to the Solicitation” and “Information About the Participants.” With respect to each of the Kellner Group Nominees, none of the events enumerated in Item 401(f)(1)-(8) of Regulation S-K of the Exchange Act occurred during the past ten years.

We do not expect that any of the Kellner Group Nominees will be unable to stand for election, but, in the event any of them is unable to serve or for good cause will not serve, the shares of Common Stock represented by the enclosed GOLD proxy card marked to vote “FOR” the Kellner Group Nominees, or if the card is signed and returned but no direction is indicated, will be voted for substitute nominee(s), to the extent this is not prohibited under the 2024 Amended Bylaws and applicable law. In addition, we reserve the right to nominate substitute person(s) if the Company makes or announces any changes to the 2024 Amended Bylaws or takes or announces any other action that has, or if consummated would have, the effect of disqualifying any Kellner Group Nominee, to the extent this is not prohibited under the 2024 Amended Bylaws and applicable law. In any such case, shares of Common Stock represented by the enclosed GOLD proxy card marked to vote “FOR” the Kellner Group Nominees, or if the card is signed and returned no direction is indicated, will be voted for such substitute nominee(s).

WE URGE YOU TO VOTE ONLY “FOR” THE ELECTION OF MR. KELLNER, MR. DEUTSCH, MR. CHIOINI AND MR. SWEENEY ON THE ENCLOSED GOLD PROXY CARD.

21

PROPOSAL 2

RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM

As discussed in further detail in the Company’s proxy statement, the Board is submitting the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2024 to the stockholders for their ratification. Additional information regarding this proposal is contained in the Company’s proxy statement.

As disclosed in the Company’s proxy statement, the failure by the stockholders to ratify the selection of the independent registered public accounting firm made by the audit committee will cause the audit committee to consider any information submitted by the stockholders in determining whether to retain BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2024.

WE MAKE NO RECOMMENDATION WITH RESPECT TO THIS PROPOSAL BUT MR. KELLNER, MR. DEUTSCH AND MR. SWEENEY INTEND TO VOTE THEIR SHARES “FOR” THIS PROPOSAL.

22

PROPOSAL 3

ADVISORY (NON-BINDING) APPROVAL OF THE COMPANY’S EXECUTIVE COMPENSATION

As disclosed in the Company’s proxy statement, under Section 14A of the Exchange Act and the rules thereunder, the Company’s stockholders are entitled to vote on a proposal to approve on an advisory (non-binding) basis, the compensation of the named executive officers. This proposal, commonly known as a “say-on-pay” proposal, is not intended to address any specific item of compensation, but rather the overall compensation of the Company’s named executive officers and the philosophy, policies and practices described in the Company’s proxy statement. Accordingly, the Company is asking stockholders to vote for the approval of the compensation of the named executive officers as disclosed in the proxy statement pursuant to the SEC’s compensation disclosure rules.

According to the Company’s proxy statement, as an advisory vote, this proposal is not binding upon the Company or the Board. However, the Compensation Committee of the Board, which is responsible for designing and overseeing the administration of the Company’s executive compensation program, will review the results of the votes and will take them into account in making a determination concerning executive compensation.

WE RECOMMEND VOTING “AGAINST” THIS PROPOSAL AND MR. KELLNER, MR. DEUTSCH AND MR. SWEENEY INTEND TO VOTE THEIR SHARES “AGAINST” THIS PROPOSAL.

23

VOTING AND PROXY PROCEDURES

Only stockholders of record on the Record Date will be entitled to notice of and to vote at the Annual Meeting. Each share of Common Stock is entitled to one vote. Stockholders who sell shares of Common Stock before the Record Date (or acquire them without voting rights after the Record Date) may not vote such shares of Common Stock. Stockholders of record on the Record Date will retain their voting rights in connection with the Annual Meeting even if they sell such shares of Common Stock after the Record Date. Based on publicly available information, we believe that the only outstanding class of securities of the Company entitled to vote at the Annual Meeting is the Common Stock.

Shares of Common Stock represented by properly executed GOLD proxy cards will be voted at the Annual Meeting as marked and, in the absence of specific instructions, will be voted “FOR” the election of each of Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney, “FOR” the ratification of the appointment of the Company’s independent registered public accounting firm, and “AGAINST” the advisory resolution to approve executive compensation, as described herein.

The Company’s current Board is composed of four directors, each with terms expiring at the Annual Meeting. Through this Proxy Statement and enclosed GOLD proxy card, we are soliciting proxies to elect Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney. We ask that you cast your votes only FOR each of Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney on the GOLD proxy card and disregard the WHITE proxy card provided by AIM. Under rules adopted by the Securities and Exchange Commission, the enclosed GOLD proxy card also includes the names of the Incumbent Nominees. We ask that you only cast your votes only FOR Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney. Stockholders should refer to the Company’s proxy statement, which is available, free of charge, at sec.gov, for the names, backgrounds, qualifications, and other information concerning the Company’s nominees. If elected, the Kellner Group Nominees will constitute the full Board and will potentially be able to implement any actions that they may believe are necessary to unlock stockholder value.

Virtual Meeting

As discussed in the Company’s proxy statement, the Company will have a virtual format for the Annual Meeting via live webcast at [●]. No in person meeting will be held. To participate in the Annual Meeting, you must pre-register at [●] by [●], Eastern Time on [●], 2024. Attendance at the Annual Meeting will be limited to stockholders as of the Record Date, their authorized representatives, and guests of the Company. Access to the Annual Meeting may be granted to others at the discretion of the Company and the chair of the Annual Meeting.

If you intend to attend the Annual Meeting virtually, please have your voting instruction form, proxy card or other communication containing your control number available and follow the instructions to complete your registration request. Upon completing registration, participants will receive further instructions via email, including unique links that will allow them to access the meeting.

Stockholders may log into the meeting platform beginning at [●], Eastern Time, on [●], 2024. If you are a beneficial holder, you must obtain a “legal proxy” from your broker, bank or other nominee in order to vote at the Annual Meeting.

If you plan to virtually attend to the Annual Meeting, we recommend you consult the Company’s proxy statement in advance for additional information about admission requirements and process.

Whether or not you plan to virtually attend the Annual Meeting, we urge you to sign, date and return the enclosed GOLD proxy card in the postage-paid envelope provided, or if your shares are held at a broker, bank or other nominee, vote via the Internet or by telephone as instructed on the GOLD voting instruction form. Additional information and our proxy materials can also be found at [●].

24

If you have any difficulty following the voting process, please call Okapi Partners at (844) 343-2621 or email info@okapipartners.com.

Quorum; Broker Non-Votes; Discretionary Voting

A quorum is the minimum number of shares of Common Stock that must be represented at a duly called meeting in person or by proxy in order to legally conduct business at the meeting under the 2024 Amended Bylaws and Delaware law. The required quorum for the transaction of business at the Annual Meeting is 40% of the shares of Common Stock entitled to vote at the Annual Meeting, or by proxy.

If your shares are held by a broker, the broker will ask you how you want your shares to be voted. Because of the contested nature of this year’s solicitation, we believe that all of the proposals on the agenda, including the ratification of the appointment of BDO USA, P.C., will be considered non-routine matters as to each holder that receives this Proxy Statement and our GOLD voting form and, accordingly, there would be no broker discretionary voting or broker non-votes with respect to your shares if you receive this Proxy Statement and our GOLD voting form. Since your broker will not have discretion to vote your shares on any proposal presented at the Annual Meeting, you must provide specific instructions to your broker as to how your shares are to be voted.

If your shares are held in street name, your broker, bank or nominee has enclosed a GOLD voting instruction card with this Proxy Statement. We strongly encourage you to vote your shares by following the instructions provided on the GOLD voting instruction form in order to ensure that your shares are represented and voted at the meeting.

Votes Required For Approval

Election of Directors – Directors will be elected by a plurality of the votes cast by holders of shares represented by proxy or present at the Annual Meeting and entitled to vote on the election of directors. Therefore, the four nominees for director who receive the most votes cast by the shares represented by proxy or present at the Annual Meeting and entitled to vote in the election will be elected at the Annual Meeting. Abstentions and withhold votes will have no effect on the outcome of Proposal 1. Broker discretionary voting is not permitted on Proposal 1, and broker non-votes, if any, will have no effect on the outcome of Proposal 1. We urge you to cast your votes only FOR each of Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney on the GOLD proxy card only.

Ratification of Appointment of Accountants – The affirmative vote of the holders of a majority in voting power of the shares of the Company’s common stock, represented by proxy or present at the Annual Meeting and entitled to vote on the matter, is required to ratify, on a non-binding advisory basis, the selection of BDO USA, P.C. (Proposal 2). If the stockholders do not ratify the appointment, according to the Company’s proxy statement, the audit committee will consider the results and any information submitted by the stockholders in determining whether to retain BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2024. Even if the appointment is ratified, the audit committee, in its discretion, may change the appointment at any time during the year if it determines that a change would be in the best interests of the Company and its stockholders. An abstention will have the same effect as a vote “against” Proposal 2. Broker non-votes, if any, will have no effect on the outcome of Proposal 2.

Advisory Vote to Approve Executive Compensation – The affirmative vote of the holders of a majority in voting power of the shares of the Company’s common stock, represented by proxy or present at the Annual Meeting and entitled to vote on the matter, is required to approve, on a non-binding advisory basis, the executive compensation of our named executive officers (Proposal 3). Although the advisory vote on Proposal 3 is non-binding – as provided by law – according to the Company’s proxy statement, the compensation committee will review the results of the vote and take them into account in making a determination concerning executive compensation. An abstention will have the same effect as a vote “against” Proposal 3. Broker non-votes, if any, will have no effect on the outcome of Proposal 3. Broker discretionary voting is not permitted on Proposal 3.

25

If you sign and submit your GOLD proxy card without specifying how you would like your shares voted, your shares will be only voted “FOR” the election of each of Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney, “FOR” the ratification of BDO USA, P.C. as the Company’s independent registered public accounting firm for the 2024 fiscal year, and “AGAINST” the advisory vote on executive compensation, and in accordance with the discretion of the persons named on the GOLD proxy card with respect to any other matters that may be voted upon at the Annual Meeting.

Revocation of Proxies

Stockholders of the Company may revoke their proxies at any time prior to exercise by attending the Annual Meeting and voting (although attendance at the Annual Meeting will not in and of itself constitute revocation of a proxy) or by delivering a written notice of revocation. The delivery of a subsequently dated proxy which is properly completed will constitute a revocation of any earlier proxy. The revocation may be delivered either to the Kellner Group in care of Okapi Partners at the address set forth on the back cover of this Proxy Statement or to the Company at 2117 SW Highway 484, Ocala, Florida 34473 or any other address provided by the Company. Although a revocation is effective if delivered to the Company, we request that either the original or photostatic copies of all revocations be mailed to us in care of Okapi Partners at the address set forth on the back cover of this Proxy Statement so that we will be aware of all revocations and can more accurately determine if and when proxies have been received. Additionally, Okapi Partners may use this information to contact stockholders who have revoked their proxies in order to solicit later dated proxies for the election of the Kellner Group Nominees.

IF YOU WISH TO VOTE FOR THE ELECTION OF MR. KELLNER, MR. DEUTSCH, MR. CHIOINI AND MR. SWEENEY TO THE BOARD, PLEASE SIGN, DATE AND RETURN PROMPTLY THE ENCLOSED GOLD PROXY CARD IN THE POSTAGE-PAID ENVELOPE PROVIDED.

26

SOLICITATION OF PROXIES

The solicitation of proxies pursuant to this Proxy Statement is being made by the Kellner Group and we intend to solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election of directors. Proxies may be solicited by mail, facsimile, telephone, Internet, in person and by advertisements.

Mr. Kellner has entered into an agreement with Okapi Partners for solicitation and advisory services in connection with this solicitation, for which Okapi Partners will receive a fee not to exceed $[●], together with reimbursement for its reasonable out-of-pocket expenses, and will be indemnified against certain liabilities and expenses, including certain liabilities under the federal securities laws. Okapi Partners will solicit proxies from individuals, brokers, banks, bank nominees and other institutional holders. We have requested banks, brokerage houses and other custodians, nominees and fiduciaries to forward solicitation materials to the beneficial owners of the shares they hold of record. Mr. Kellner will reimburse these record holders for their reasonable out-of-pocket expenses in so doing. It is anticipated that Okapi Partners will employ approximately [●] persons to solicit stockholders for the Annual Meeting.

Costs of this solicitation of proxies are currently estimated to be approximately $[●] million (including, but not limited to, fees for attorneys, solicitors and other advisors, and other costs incidental to the solicitation). We estimate that through the date hereof expenses in furtherance of, or in connection with, the solicitation are approximately $[●]. The actual amount could be higher or lower depending on the facts and circumstances arising in connection with any solicitation. Mr. Kellner will bear the costs of this solicitation.

Mr. Kellner intends to seek reimbursement from the Company of all expenses he incurs in connection with this solicitation (including, for the avoidance of doubt, any related litigation expenses), and does not intend to submit the question of such reimbursement to a vote of security holders of the Company. In addition, each of Mr. Kellner, Mr. Deutsch and Mr. Chioini intend to seek reimbursement from the Company of all expenses they incurred in connection with their solicitation for the 2023 Annual Meeting (including related litigation expenses), and they do not intend to submit the question of such reimbursement to a vote of security holders of the Company. See “Information About the Participants” for information about these fees. The 2024 Agreement provides, however, that nothing therein will constitute a commitment or assurance that any party would vote a certain way if elected or appointed as a director of the Company or otherwise limit or interfere with a party’s ability to comply, if elected or appointed as a director of the Company, with such party’s fiduciary duties under applicable law. As such, any decision, as a director, to approve reimbursement would be made only to the extent consistent with applicable fiduciary duties.

The Kellner Group does not intend to seek reimbursement for expenses incurred by Mr. Chioini and others under the 2022 Group Agreement.

27

INFORMATION ABOUT THE PARTICIPANTS

The participants in the solicitation being made pursuant to this Proxy Statement are Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney. See the section entitled “Proposal 1 – Election of Directors” for certain information regarding each of us.

As of the date hereof, Mr. Kellner is the beneficial owner of 1,493,000 shares of Common Stock (1,000 of which he is the record owner of), Mr. Deutsch is the beneficial owner of 1,716,100 shares of Common Stock and Mr. Sweeney is the beneficial owner of 2,000 shares of Common Stock. Mr. Chioini does not beneficially own any shares of Common Stock. Together, the beneficial ownership of the Kellner Group is 3,211,100 shares of Common Stock, or approximately [●]% of the [●] shares outstanding as of the Record Date.

Certain of Mr. Kellner’s family members are or may be deemed the beneficial owners of an aggregate of 479,000 additional shares of Common Stock. These shares of Common Stock are generally held in trusts or a family foundation over which Mr. Kellner’s wife, brother and/or adult children and in-laws have voting and dispositive power. Of these 479,000 additional shares of Common Stock, 210,000 of which can be considered to be beneficially owned by “associates” of Mr. Kellner because they are held by a family foundation (the Kelben Foundation) of which Mr. Kellner’s spouse, Mary Kellner, is manager and a trust of which Ms. Kellner is trustee. The Kelben Foundation and Ms. Kellner share the same business address as Mr. Kellner. Although Mr. Kellner could be deemed to beneficially own these additional shares of Common Stock, Mr. Kellner disclaims beneficial ownership of these additional shares of Common Stock.

Mr. Deutsch’s parents are the beneficial owners of an aggregate of 60,000 additional shares of Common Stock. Mr. Deutsch disclaims beneficial ownership of these additional shares of Common Stock.

Schedule I hereto set forth all purchases and sales effected during the past two years by any participant with respect to securities of the Company.

As noted above, Mr. Kellner intends to seek reimbursement of expenses he incurs in connection with this proxy solicitation and any related litigation. In addition, as noted above, Mr. Kellner, Mr. Deutsch and Mr. Chioini intend to seek reimbursement from the Company for their expenses they incurred in connection with their solicitation for the 2023 Annual Meeting (including related litigation expenses). Mr. Kellner has separately submitted the Fee Reimbursement Request for certain of these expenses. Therefore, to the extent they seek reimbursement, each of Mr. Kellner, Mr. Deutsch and Mr. Chioini could be considered to have an interest in the outcome of the election at the Annual Meeting to the extent of the expenses they have incurred. The total expenses of Mr. Kellner, Mr. Deutsch and Mr. Chioini with respect to the nominations, proxy solicitation and related litigation with respect to the 2023 Annual Meeting were approximately $5.3 million (of which the Mr. Kellner paid approximately $4.0 million, Mr. Deutsch paid approximately $0.9 million and Mr. Chioini paid approximately $0.3 million). Any reimbursement for such expenses is expected to be allocated in the priority set forth in the 2023 Group Agreement.

The Kellner Group does not intend to seek reimbursement for expenses incurred by Mr. Chioini and others under the 2022 Group Agreement. However, Mr. Chioini could still be considered to have an interest in the outcome of the election at the Annual Meeting due to his joint responsibility for expenses that continue to be incurred under the 2022 Group Agreement in connection with ongoing litigation in the Florida Section 13(d) Action and the Jorgl Delaware Action, in which AIM has filed a motion for fee shifting (and Mr. Jorgl also filed a motion against AIM for more limited fee shifting). These proceedings are still pending. The additional costs that may be incurred in litigating them or as result of the outcomes of the proceedings could result in additional expense for which Mr. Chioini is jointly responsible. For reference, approximately $2.3 million in aggregate expenses have been incurred to date under the 2022 Group Agreement, for which Mr. Chioini and Mr. Xirinachs are jointly responsible, of which approximately $0.35 million have been paid to date, with the remainder outstanding. A significant majority of the expenses actually paid to date have been paid by Mr. Chioini.

28

Mr. Kellner and Mr. Deutsch are parties adverse to the Company in the Florida Section 13(d) Action. Mr. Kellner has also submitted the Section 220 Demand and Fee Reimbursement Request to the Company, which could potentially result in additional proceedings. Mr. Chioini has a material interest adverse to the Company in the Florida Section 13(d) Action and Jorgl Delaware Action due to his joint responsibility for expenses under the 2022 Group Agreement

Except as set forth in this Proxy Statement, (i) during the past ten years, no participant in this solicitation has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); (ii) no part of the purchase price or market value of the securities of the Company owned by any participant in this solicitation is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities; (iii) no participant in this solicitation is, or within the past year was, a party to any contract, arrangements or understandings with any person with respect to any securities of the Company, including, but not limited to, joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies; (iv) no associate of any participant in this solicitation owns beneficially, directly or indirectly, any securities of the Company; (v) no participant in this solicitation owns beneficially, directly or indirectly, any securities of any parent or subsidiary of the Company; (vi) no participant in this solicitation or any of his, her or its associates was a party to any transaction, or series of similar transactions, since the beginning of the Company’s last fiscal year, or is a party to any currently proposed transaction, or series of similar transactions, to which the Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $120,000; (vii) no participant in this solicitation or any of his, her or its associates has any arrangement or understanding with any person with respect to any future employment by the Company or its affiliates, or with respect to any future transactions to which the Company or any of its affiliates will or may be a party; (viii) no participant in this solicitation has a substantial interest, direct or indirect, by securities holdings or otherwise, in any matter to be acted on at the Annual Meeting; (ix) no participant in this solicitation holds any positions or offices with the Company; (x) no participant in this solicitation has a family relationship with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer; (xi) no companies or organizations, with which any of the participants in this solicitation has been employed in the past five years, is a parent, subsidiary or other affiliate of the Company; and (xii) no participant in this solicitation or any of his, her or its associates is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries in any material proceedings. See “Background to the Solicitation” above.

29

OTHER MATTERS AND ADDITIONAL INFORMATION

We are unaware of any other matters to be considered at the Annual Meeting. However, should other matters, which we are not aware of a reasonable time before this solicitation, be brought before the Annual Meeting, the persons named as proxies on the enclosed GOLD proxy card will vote on such matters in their discretion.

STOCKHOLDER PROPOSALS

Stockholder Proposals under Rule 14a-8

Pursuant to rules promulgated by the SEC, stockholders interested in submitting a proposal to be considered for inclusion in the Company’s proxy materials and for presentation at the Company’s 2025 Annual Meeting may do so by following the procedures set forth in Rule 14a-8 under the Exchange Act. In general, to be eligible for inclusion in the Company’s proxy materials, Rule 14a-8 stockholder proposals must be received by the Company’s Corporate Secretary at the Company’s principal executive offices (located at 2117 SW Highway 484, Ocala, Florida 34473) no later than [●].

Stockholder Proposals

Any stockholder of record of the Company who desires to submit a proposal of business (other than stockholder proposals in accordance with Rule 14a-8) for action at the 2025 Annual Meeting must deliver written notice of an intent to make such proposal of business to the Company’s Corporate Secretary at c/o Corporate Secretary, AIM ImmunoTech Inc., 2117 SW Highway 484, Ocala, Florida 34473 no earlier than [●] and no later than [●]. However, if the date of the 2025 Annual Meeting is more than 30 days before or after the anniversary of the date of the prior year’s annual meeting, then such notice must be delivered to the Company’s Secretary no earlier than 120 days prior to the 2025 Annual Meeting and no later than the close of business on the later of 90 days prior to the 2025 Annual Meeting and the 10th day following the day on which public announcement (as defined in the 2024 Amended Bylaws) of the date of the 2025 Annual Meeting is first made by the Company. Any such notice must also comply with the timing, disclosure, procedural and other requirements as set forth in the 2024 Amended Bylaws.

Stockholder Nominations for Director Candidates

Any stockholder of record of the Company who desires to nominate one or more director candidates at the 2025 Annual Meeting or submit a proposal of business (other than stockholder proposals in accordance with Rule 14a-8) for action at the 2025 Annual Meeting must deliver written notice of an intent to make such director nomination and/or make such proposal of business to the Company’s Corporate Secretary at c/o Corporate Secretary, AIM ImmunoTech Inc., 2117 SW Highway 484, Ocala, Florida 34473 no earlier than [●] and no later than [●]. However, if the date of the 2025 Annual Meeting is more than 30 days before or after the anniversary of the date of the prior year’s annual meeting, then such notice must be delivered to the Company’s Secretary no earlier than 120 days prior to the 2025 Annual Meeting and no later than the close of business on the later of 90 days prior to the 2025 Annual Meeting and the 10th day following the day on which public announcement (as defined in the 2024 Amended Bylaws) of the date of the 2025 Annual Meeting is first made by the Company. Any such notice must also comply with the timing, disclosure, procedural and other requirements as set forth in the 2024 Amended Bylaws.

In addition to satisfying the requirements under the 2024 Amended Bylaws described in the immediately preceding paragraph, to comply with the universal proxy rules under the Exchange Act, any stockholder who intends to solicit proxies in support of director nominees other than the Board’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act in accordance with the time period set forth immediately above for providing notice of stockholder nominations for director candidates.

30

The information set forth above regarding the procedures for submitting stockholder proposals for consideration at the 2025 Annual Meeting is based on information contained in the Company’s proxy statement for the Annual Meeting. The incorporation of this information in this Proxy Statement should not be construed as an admission by the Kellner Group that such procedures are legal, valid or binding.

31

HOUSEHOLDING

Some record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of this Proxy Statement may have been sent to multiple stockholders in your household. The Kellner Group will promptly deliver a separate copy of the document to you if you write to our proxy solicitor, Okapi Partners, at the following address or phone number: 1212 Avenue of the Americas, 17th Floor, New York, NY 10036 or call toll free at (844) 343-2621. If you want to receive separate copies of proxy materials in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact the Company, or you may contact our proxy solicitor at the above address and phone number.

32

INCORPORATION BY REFERENCE

WE HAVE OMITTED FROM THIS PROXY STATEMENT CERTAIN DISCLOSURE REQUIRED BY APPLICABLE LAW THAT IS EXPECTED TO BE INCLUDED IN THE COMPANY’S PROXY STATEMENT RELATING TO THE ANNUAL MEETING BASED ON RELIANCE ON RULE 14A-5(C). THIS DISCLOSURE IS EXPECTED TO INCLUDE, AMONG OTHER THINGS, CURRENT BIOGRAPHICAL INFORMATION ON THE COMPANY’S DIRECTORS, INFORMATION CONCERNING EXECUTIVE COMPENSATION, AND OTHER IMPORTANT INFORMATION. SEE SCHEDULE II FOR INFORMATION REGARDING PERSONS WHO BENEFICIALLY OWN MORE THAN 5% OF THE SHARES AND THE OWNERSHIP OF THE SHARES BY THE DIRECTORS AND MANAGEMENT OF THE COMPANY.

The information concerning the Company contained in this Proxy Statement (including Schedule II attached hereto) has been taken from, or is based upon, publicly available information. The SEC maintains a website that contains periodic and current reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, which are made available, free of charge, at sec.gov.

Ted D. Kellner

Todd Deutsch

Robert L. Chioini

Paul W. Sweeney

[●], 2024

33

SCHEDULE I

PURCHASES AND SALES OF COMPANY SECURITIES IN PAST TWO YEARS

34

SCHEDULE II

The following table is reprinted from the Company’s definitive proxy statement filed with the Securities and Exchange Commission on [●], 2024.

PRINCIPAL STOCKHOLDERS

The following table sets forth as of the Record Date, [●], 2024, the number and percentage of outstanding shares of common stock beneficially owned by:

35

IMPORTANT

Tell your Board what you think! Your vote is important. No matter how many shares of Common Stock you own, please give the Kellner Group your proxy FOR the election of the Kellner Group Nominees and in accordance with the Kellner Group’s recommendations on the other proposals on the agenda for the Annual Meeting by taking three steps:

You may vote your shares at the Annual Meeting, however, even if you plan to attend the Annual Meeting, we recommend that you submit your GOLD proxy card by mail by the applicable deadline so that your vote will still be counted if you later decide not to attend the Annual Meeting. If any of your shares of Common Stock are held in the name of a brokerage firm, bank, bank nominee or other institution, only it can vote such shares of Common Stock and only upon receipt of your specific instructions. Depending upon your broker or custodian, you may be able to vote either by toll-free telephone or by the Internet. Please refer to the enclosed voting form for instructions on how to vote electronically. You may also vote by signing, dating and returning the enclosed GOLD voting form.

If you have any questions, require assistance in voting your GOLD proxy card, or need additional copies of the Kellner Group’s proxy materials, please contact Okapi Partners at the phone numbers or email address listed below.

Okapi Partners LLC

1212 Avenue of the Americas, 17th Floor,

New York, New York 10036

Stockholders may call toll-free: (844) 343-2621

Banks and brokers call: (212) 297-0720

Email: info@okapipartners.com

36

PRELIMINARY COPY SUBJECT TO COMPLETION DATED OCTOBER 18, 2024

GOLD PROXY CARD

AIM IMMUNOTECH INC.

2024 ANNUAL MEETING OF STOCKHOLDERS

THIS PROXY IS SOLICITED ON BEHALF OF THE KELLNER GROUP IN ITS PROXY SOLICITATION

THE BOARD OF DIRECTORS OF AIM IMMUNOTECH INC.

IS NOT SOLICITING THIS PROXY

PROXY

The undersigned appoints [●], [●], and [●], and each of them, attorneys and agents with full power of substitution to vote all shares of common stock of AIM ImmunoTech Inc. (the “Company”) which the undersigned would be entitled to vote if personally present at the 2024 Annual Meeting of Stockholders of the Company scheduled to be held on [●], 2024 at [●], Eastern Time, in a virtual meeting format, via live webcast (including any adjournments or postponements thereof and any meeting called in lieu thereof, the “Annual Meeting”).

The undersigned hereby revokes any other proxy or proxies heretofore given to vote or act with respect to the shares of common stock of the Company held by the undersigned, and hereby ratifies and confirms all action the herein named attorneys and proxies, their substitutes, or any of them may lawfully take by virtue hereof. If properly executed, this Proxy will be voted as directed on the reverse and in the discretion of the herein named attorneys and proxies or their substitutes with respect to any other matters as may properly come before the Annual Meeting that are unknown to Mr. Kellner, Mr. Deutsch, Mr. Chioini and Mr. Sweeney (the “Kellner Group”) a reasonable time before this solicitation.

IF NO DIRECTION IS INDICATED WITH RESPECT TO THE PROPOSALS ON THE REVERSE, THIS PROXY WILL BE ONLY VOTED “FOR” TED D KELLNER, TODD DEUTSCH, ROBERT L. CHIOINI AND PAUL W. SWEENEY ON PROPOSAL 1, “FOR” PROPOSAL 2, AND “AGAINST” PROPOSAL 3.

This Proxy will be valid until the completion of the Annual Meeting. This Proxy will only be valid in connection with the Kellner Group’s solicitation of proxies for the Annual Meeting.

IMPORTANT: PLEASE SIGN, DATE AND MAIL THIS PROXY CARD PROMPTLY!

CONTINUED AND TO BE SIGNED ON REVERSE SIDE

GOLD PROXY CARD

☒ Please mark vote as in this example

THIS PROXY WILL BE VOTED AS DIRECTED. IF NO DIRECTION IS INDICATED WITH RESPECT TO THE PROPOSALS, THIS PROXY WILL BE ONLY VOTED “FOR” TED D. KELLNER, TODD DEUTSCH, ROBERT L. CHIOINI AND PAUL W. SWEENEY IN PROPOSAL 1, “FOR” PROPOSAL 2, AND “AGAINST” PROPOSAL 3. IF LESS THAN FOUR “FOR” VOTES ARE INDICATED IN PROPOSAL 1, THIS PROXY WILL BE VOTED ONLY FOR THOSE NOMINEES INDICATED.

THE KELLNER GROUP STRONGLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” ONLY TED D. KELLNER, TODD DEUTSCH, ROBERT L. CHIOINI AND PAUL W. SWEENEY IN PROPOSAL 1, MAKES NO RECOMMENDATION WITH RESPECT TO PROPOSAL 2, AND RECOMMENDS THAT STOCKHOLDERS VOTE “AGAINST” PROPOSAL 3.

The Kellner Group does not expect that any of its nominees will be unable to stand for election, but, in the event any of its nominees are unable to serve or for good cause will not serve, the shares of Common Stock represented by this proxy card and marked to vote “FOR” the Kellner Group nominee, or if the card is signed and returned and no direction is indicated, will be voted for substitute nominee(s), to the extent this is not prohibited under the Company’s organizational documents and applicable law. In addition, the Kellner Group has reserved the right to nominate substitute person(s) if the Company makes or announces any changes to its organizational documents or takes or announces any other action that has, or if consummated would have, the effect of disqualifying any nominee, to the extent this is not prohibited under the Company’s organizational documents and applicable law. In any such case, shares of Common Stock represented by this proxy card and marked to vote “FOR” the Kellner Group nominee, or if the card is signed and returned and no direction is indicated, will be voted for such substitute nominee(s). Stockholders should refer to the Company’s proxy statement, which is available, free of charge, at sec.gov, for the names, backgrounds, qualifications and other information concerning the Incumbent Nominees.

THERE IS NO ASSURANCE THAT ANY OF THE CANDIDATES WHO HAVE BEEN NOMINATED BY THE COMPANY WILL SERVE AS DIRECTORS IF OUR NOMINEES ARE ELECTED.

Please sign exactly as name appears on stock certificates or on label affixed hereto. When shares of Common Stock are held by joint tenants, both should sign. In case of joint owners, EACH joint owner should sign. When signing as attorney, executor, administrator, trustee, guardian, corporate officer, etc., give full title as such.

PLEASE SIGN, DATE AND MAIL YOUR PROXY PROMPTLY IN THE POSTAGE-PAID ENVELOPE ENCLOSED.